^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Zaltrap (ziv-aflibercept IV) (VEGF-A inhibitor, PIGF inhibitor, VEGF-B inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Is antiangiogenic therapy necessary for patients with metastatic colorectal cancer (mCRC) and mutation in the BRAF gene? Results of the systematic review and meta-analysis
Published date:
01/11/2021
Excerpt:
...compared chemotherapy (CT) plus bevacizumab or aflibercept or ramucirumab and CT alone at the first-line or second-lines with information of the BRAF status... a tendency for significant improvement in PFS (HR 0.64, 95% CI 0.4-1.02; p = 0.06; I2 = 0%, p for heterogeneity 0.7; 53trials) and significant improvement in OS (HR 0.51, 95% CI 0.32-0.82; p = 0.005; I2 = 0%, p for heterogeneity 0.52; 4 trials) in group of ani-angiogenic therapy. Addition of anti-angiogenic therapy to chemotherapy showed improvement in the PFS and OS in pts with mBRAF compared with chemotherapy alone.
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
Targeted therapy for advanced colorectal cancer patients. Terapia mirata per il trattamento dei pazienti con carcinoma metastatico del colon-retto.
Excerpt:
...Assessed tumour EGFR pathway mutational status (K-RAS, N-RAS), BRAF, HER-2 neu, MSI.5. ...
Trial ID:
